QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)

Exelixis (EXEL) Stock Forecast & Price Target

$21.71
-0.25 (-1.14%)
(As of 02/27/2024 ET)

Exelixis Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 17 Analyst Ratings

Analysts' Consensus Price Target

$25.94
19.47% Upside
High Forecast$32.00
Average Forecast$25.94
Low Forecast$18.00
TypeCurrent Forecast
2/27/23 to 2/27/24
1 Month Ago
1/28/23 to 1/28/24
3 Months Ago
11/29/22 to 11/29/23
1 Year Ago
2/27/22 to 2/27/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
7 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.94$26.00$25.44$26.27
Predicted Upside19.47% Upside24.52% Upside28.03% Upside48.17% Upside
Get Exelixis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.


EXEL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EXEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Exelixis Stock vs. The Competition

TypeExelixisMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.67
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside19.47% Upside1,864.50% Upside7.71% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/7/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$26.00 ➝ $28.00+35.46%
2/2/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$23.00 ➝ $25.00+16.44%
1/30/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$24.00 ➝ $25.00+14.21%
1/26/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
12/19/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+15.68%
12/15/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$31.00+32.99%
12/14/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$27.00+14.89%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$22.00 ➝ $23.00+14.26%
10/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$25.00 ➝ $27.00+25.58%
10/11/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$30.00+39.28%
9/26/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$28.00+28.26%
9/13/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$32.00+45.12%
8/22/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$25.00 ➝ $29.00+35.70%
8/8/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Liu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
8/8/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$18.00-11.11%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$18.00-11.11%
3/9/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$23.00+40.59%
3/3/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$24.00+43.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:02 PM ET.












EXEL Price Target - Frequently Asked Questions

What is Exelixis's consensus rating and price target?

According to the issued ratings of 17 analysts in the last year, the consensus rating for Exelixis stock is Moderate Buy based on the current 5 hold ratings and 12 buy ratings for EXEL. The average twelve-month price prediction for Exelixis is $25.94 with a high price target of $32.00 and a low price target of $18.00. Learn more on EXEL's analyst rating history.

Do Wall Street analysts like Exelixis more than its competitors?

Analysts like Exelixis more than other Medical companies. The consensus rating score for Exelixis is 2.71 while the average consensus rating score for medical companies is 2.68. Learn more on how EXEL compares to other companies.

Does Exelixis's stock price have much upside?

According to analysts, Exelixis's stock has a predicted upside of 23.56% based on their 12-month stock forecasts.

What analysts cover Exelixis?

Exelixis has been rated by Barclays, BTIG Research, Citigroup, JMP Securities, Royal Bank of Canada, Stifel Nicolaus, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:EXEL) was last updated on 2/27/2024 by MarketBeat.com Staff